Last edition
News about "Yesafili "
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili
Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.
Yesafili | 09/07/2026 | By News Bureau
Biocon Biologics Gets FDA Approval for Biosimilar Aflibercept for Yesafili
Biocon Biologics Ltd (BBL) has announced that the US Food and Drug Administration (US FDA) has approved the company’s first-to-file application for Yesafili.
Yesafili | 21/05/2024 | By Aishwarya | 613
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy